June 7, 2021 5:49pm

But, worried as the upside is blanket algorithmic volume play

Pre-open indications: 6 HITs and 2 MISS

My comments try to distinguish the temporary from real pricing digression or progress.

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

The Dow closed DOWN -126.15 points (-0.36%); the S&P closed DOWN -3.37 points (-0.08%) while the Nasdaq closed UP +67.23 points (+0.49%)

 

Henry’omics:

Major stock benchmarks came off a winning week …

Sentiment is transitory i.e., fleeting … as Biogen (BIB) stock jumps on FDA approval as the pop in the stock was even more breath-taking than what analysts had predicted, but seems consistent with the FDA's action, which took even Biogen bulls by surprise.

The cell and gene therapy sector equites climbed on Monday as the oversold were” recognized”.

The macro market perspective is “with” us as the decision is a BIG deal for the sector!

Another POSITIVE … The FDA has lifted the clinical hold on P1/2 HGB-206 and P3 HGB-210 studies of bluebird Bio (BLUE) LentiGlobin for sickle cell disease and two P3 studies of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.

  • BLUE is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible.
  • In March, BLUE said that based on the analyses completed to date, it is very unlikely the suspected unexpected serious adverse reaction of acute myeloid leukemia in its P1/2 study of LentiGlobin was related to the BB305 lentiviral vector.
  • BLUE shares are up +3.33% at $32.07 – I had a BUY this a.m.

Watch about below as the IBB is up +3.44% and the XBI is up +4.62% …?

 

RegMed Investors’ (RMi) pre-open: “risk, not too hot but, not to cool to ponder moves. Key word: expectation amidst a trolly-ride of share pricing, the views can’t be beaten yet the dips are memorable.” … https://www.regmedinvestors.com/articles/11943

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Monday opened positive at 21/12, 1 flat and 1 acquired, stayed positive at the mid-day to 30/14, 2 flats and 1 acquired, closing positive at 30/4, 1 flat and 1 acquired;

 

The Biostage (BSTG) Chronicles: The “pump and promote” is BACK but NOT quite working as 2,350 shares traded dropping the stock -$0.17 to $1.13 after Friday’s as 800 shares traded pumping the stock +$0.19 to $1.30, Thursday’s 3528 shares traded with no pricing advantage after Wednesday’s flat at $1.11 with 5,673 shares were traded and the stock was down -$0.11 to $1.11; WHO is buying this “zombie”?

 

Pre-open Indications: 6 HITs <Biostage (BSTG -$0.17), bluebird bio (BLUE +$1.06), CRISPR Therapeutics (CRSP +$5.91), Editas Medicine (EDIT +$1.84), uniQure NV (QURE +$1.85), Sage Therapeutics (SAGE +$2.86) and 2 MISS < Homology Medicine (FIXX +$0.25), Global Blood Therapeutics (GBT +$0.85)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … MESO added: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Fate Therapeutics (FATE), Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE) to name 5 of the 30 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), Biostage (BSTG), Mesoblast (MESO), Pluristem (PSTI) to name 4 of the 4 inclining of the 35 covered

 

Key metrics:

  • Sector volume was DEFINETELY INCREASED with 16 of the 30-upside having higher than the 3-month average volume with the volume of 3 of 4-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 30-upside were +1.79% (AXGN) to +8.84% (BCLI) while the 4-downside ranges from -1.18% (RENE.L) to -13.08% (BSTG);

 

Monday’s (10 of 30) incliners:

  • CRISPR Therapeutics (CRSP +$5.91 after Friday’s +$3.46);
  • Intellia Therapeutics (NTLA +$5.42 after Friday’s +$0.73);
  • Alnylam Pharmaceuticals (ALNY +$4.86 after Friday’s -$1.69);
  • Fate Therapeutics (FATE +$4.21 after Friday’s +$5.54);
  • Ultragenyx (RARE +$3.30 after Friday’s -$2.18);
  • Sage Therapeutics (SAGE +$2.86 after Friday’s +$1.05);
  • Vericel (VCEL +$2.65 after Friday’s +$0.98);
  • BioLife Solutions (BLFS +$2.19 after Friday’s +$1.07);
  • Regenxbio (RGNX +$1.87 after Friday’s +$0.88);
  • uniQure NV (QURE +$1.85);

Monday’s (4 of 4) decliners:

  • ReNeuron (REN.L -$1.50 after Friday’s +$1.00;
  • Biostage (BSTG -$0.17 after Friday’s +$0.19);
  • Mesoblast (MESO -$0.15);
  • Pluristem (PSTI -$0.10 after Friday’s +$0.59);

Closing 1 -Stemline Therapeutics (STML – acquired)

 

COVID-19 updates:

More than half of Americans have received at least one dose of a vaccine and 42% are fully vaccinated.

Friday’s COVID Data Tracker <Million>:

  • Cases: 34,211 M
  • Death rate totaled 612,387
  • Recovered/Discharged 28,123,250

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed up +3.44% and XBI closed up +4.62%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was flat at 0.00 points or 0.00% at 16.42

Upside volume: poppin'

  • Monday: 16 out of the 30-upside had higher than the 3-month average volume;

Downside volume: 

  • Monday: 3 out of the 4-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: LOW % with limited pricing drops as upside maintains

  • Monday’s percentage (%) of the 30-upside were +1.79% (AXGN) to +8.84% (BCLI) while the 4-downside ranges from -1.18% (RENE.L) to -13.08% (BSTG);

 

June, third month of Q2/21:

Monday closed positive with 30 advancers, 4 decliners and 1 acquired

Friday closed positive with 25 advancers, 8 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: What changes, it might just pay to read … I haven’t been wrong, as I had stated “Key word: expectation amidst a trolly-ride of share pricing, the views can’t be beaten yet the dips are memorable.”

Expect the sector rotation trades to continue to play out. – I’d be SELLING into STRENGTH on Tuesday.

Today, the upside was recognized again – it was in the cards!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

My time frame of measurement remains Friday to Friday and has been proved right again, don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.